Related Experiment Videos
Pediatric cardiac transplantation: management issues
1Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Insights
Pediatric heart transplantation offers excellent survival rates for children with end-stage heart disease. Advances in immunosuppression improve outcomes, though graft coronary artery disease remains a long-term challenge.
Area of Science:
- Pediatric Cardiology
- Transplantation Medicine
- Immunology
Background:
- Pediatric heart transplantation is a vital treatment for end-stage heart disease in children.
- Survival rates for pediatric heart recipients are high, with long-term survival extending for decades.
- Significant advancements in immunosuppression have improved patient outcomes and reduced side effects.
Purpose of the Study:
- To review key management issues in pediatric heart transplant recipients.
- To incorporate protocols from the Stanford University Pediatric Heart Transplant Program.
- To highlight current challenges and future directions in the field.
Main Methods:
- Review of current literature on pediatric heart transplantation.
- Analysis of survival data and complication rates.
- Incorporation of clinical experience and protocols from a leading transplant center.
Main Results:
- High one-year survival rates (89-92%) and excellent long-term prognosis for pediatric heart recipients.
- Improved efficacy and reduced toxicity of modern immunosuppressive therapies.
- Early complications like acute rejection and infection have decreased significantly post-transplant.
Conclusions:
- Pediatric heart transplantation is a successful therapy with improving outcomes due to advancements in immunosuppression.
- Graft coronary artery disease remains the primary obstacle to long-term graft survival.
- A shortage of pediatric donors limits the number of heart transplants performed annually.
Abstract:
Pediatric heart transplantation is an effective therapeutic modality for children with end-stage heart disease. The overall survival of young heart recipients is very good: 89% to 92% one year survival. Survival data for the long term indicates that pediatric heart recipients have a very good chance of living for decades. Advances in immunosuppression have lent optimism for the future. There are now alternatives in induction, maintenance, and acute rejection therapy. Immunosuppressants are more specific in action and prevent and treat allograft rejection with less toxic side effects and decreased morbidity. Acute rejection and infection are early complications that reduce in incidence significantly after six months post-transplant. Graft coronary artery disease continues to be the most significant hurdle to long-term survival. Currently there is a plateau in the number of heart transplants performed annually. Lack of available pediatric donors plays a large role in the paucity of pediatric transplants. This review focuses on the key management issues involved in the care of the pediatric heart transplant recipient and incorporates the experiences and protocols of the Stanford University Pediatric Heart Transplant Program.